Adipiplon

From WikiMD's WELLNESSPEDIA

Adipiplon


Adipiplon is a nonbenzodiazepine hypnotic drug that was developed for the treatment of insomnia. It functions as a GABAA receptor agonist, specifically targeting the α3 subunit of the receptor. Adipiplon was designed to provide the sedative effects necessary for sleep induction and maintenance without the side effects commonly associated with benzodiazepines.

Mechanism of Action[edit]

Adipiplon works by binding to the GABAA receptor, which is a type of ligand-gated ion channel in the central nervous system. By enhancing the effect of the neurotransmitter gamma-aminobutyric acid (GABA) at this receptor, adipiplon increases chloride ion influx into neurons, leading to hyperpolarization and decreased neuronal excitability. This results in a sedative effect, making it easier for individuals to fall asleep and stay asleep.

Pharmacokinetics[edit]

The pharmacokinetics of adipiplon involve its absorption, distribution, metabolism, and excretion. After oral administration, adipiplon is rapidly absorbed into the bloodstream. It is metabolized primarily in the liver by the cytochrome P450 enzyme system, particularly CYP3A4. The metabolites are then excreted via the kidneys.

Clinical Trials[edit]

Adipiplon has undergone several clinical trials to evaluate its efficacy and safety in treating insomnia. These trials have shown that adipiplon is effective in reducing the time to sleep onset and increasing total sleep time. However, some trials have also reported side effects such as dizziness, headache, and nausea.

Side Effects[edit]

Common side effects of adipiplon include:

Less common but more severe side effects may include:

Regulatory Status[edit]

As of the latest updates, adipiplon has not been approved by major regulatory agencies such as the Food and Drug Administration (FDA) for clinical use. Further studies are required to fully establish its safety profile and therapeutic efficacy.

See Also[edit]

References[edit]

External Links[edit]


Sponsored Health Resource

W8MD weight loss success

W8MD Weight Loss, Sleep & MedSpa

Looking for physician-supervised weight loss, semaglutide, tirzepatide, or GLP-1 receptor agonist options? W8MD helps eligible patients in New York City, Brooklyn, New Jersey, Connecticut, Pennsylvania, Delaware, and greater Philadelphia with medical weight loss, sleep medicine, and long-term maintenance support.

GLP-1 specials: Affordable GLP-1 injections NYC and Philadelphia starting from $29.99/week and up for semaglutide with insurance accepted for qualifying visits, and $45/week and up for tirzepatide with insurance accepted for qualifying visits. Self-pay options start from $59.99/week and up for semaglutide and $69.99/week and up for tirzepatide.

Book a W8MD appointment · View GLP-1 specials

Paid promotional message. Eligibility, pricing, insurance coverage, medication availability, and results vary. Medical evaluation required.

Medical Disclaimer: WikiMD is for informational purposes only and is not a substitute for professional medical advice. Content may be inaccurate or outdated and should not be used for diagnosis or treatment. Always consult your healthcare provider for medical decisions. Verify information with trusted sources such as CDC.gov and NIH.gov. By using this site, you agree that WikiMD is not liable for any outcomes related to its content. See full disclaimer.

Credits:Most images are courtesy of Wikimedia commons, and templates, categories Wikipedia, licensed under CC BY SA or similar.